These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23638089)

  • 21. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
    Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
    Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secreted Protein Acidic and Rich in Cysteine (
    Arqueros C; Salazar J; Gallardo A; Andrés M; Tibau A; Lidia Bell O; Artigas A; Lasa A; Ramón Y Cajal T; Lerma E; Barnadas A
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease.
    Gong DH; Fan L; Chen HY; Ding KF; Yu KD
    Oncotarget; 2016 May; 7(19):28570-8. PubMed ID: 27086913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
    Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
    Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
    Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
    BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
    Kim SH; Jung KH; Kim TY; Im SA; Choi IS; Chae YS; Baek SK; Kang SY; Park S; Park IH; Lee KS; Choi YJ; Lee S; Sohn JH; Park YH; Im YH; Ahn JH; Kim SB; Kim JH
    Cancer Res Treat; 2016 Oct; 48(4):1373-1381. PubMed ID: 27034147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
    Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
    J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
    Prenzel KL; Warnecke-Eberz U; Xi H; Brabender J; Baldus SE; Bollschweiler E; Gutschow CA; Hölscher AH; Schneider PM
    Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.
    Dennison JB; Molina JR; Mitra S; González-Angulo AM; Balko JM; Kuba MG; Sanders ME; Pinto JA; Gómez HL; Arteaga CL; Brown RE; Mills GB
    Clin Cancer Res; 2013 Jul; 19(13):3703-13. PubMed ID: 23697991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
    Psyrri A; Kalogeras KT; Wirtz RM; Kouvatseas G; Karayannopoulou G; Goussia A; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Economopoulou P; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
    J Transl Med; 2017 Feb; 15(1):30. PubMed ID: 28193231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N; Yau C; Li J; Esserman LJ; Rugo HS
    Breast Cancer Res Treat; 2017 Aug; 165(1):129-138. PubMed ID: 28577080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC.
    Güttlein LN; Benedetti LG; Fresno C; Spallanzani RG; Mansilla SF; Rotondaro C; Raffo Iraolagoitia XL; Salvatierra E; Bravo AI; Fernández EA; Gottifredi V; Zwirner NW; Llera AS; Podhajcer OL
    Mol Cancer Res; 2017 Mar; 15(3):304-316. PubMed ID: 28031408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
    Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
    Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer.
    Yamanaka M; Kanda K; Li NC; Fukumori T; Oka N; Kanayama HO; Kagawa S
    J Urol; 2001 Dec; 166(6):2495-9. PubMed ID: 11696817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between secreted protein acidic and rich in cysteine protein expression and the prognosis of postoperative patients exhibiting esophageal squamous cell carcinoma.
    Wu J; Zhang JR; Jiang XQ; Cao XG
    Mol Med Rep; 2017 Sep; 16(3):3401-3406. PubMed ID: 28713937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of SPARC gene polymorphisms rs3210714 and rs7719521 with VEGF expression and utility of Nottingham Prognostic Index scoring in breast cancer in a sample of Egyptian women.
    Bawazeer S; Sabry D; Mahmoud RH; Elhanbuli HM; Yassen NN; Abdelhafez MN
    Mol Biol Rep; 2018 Dec; 45(6):2313-2324. PubMed ID: 30259245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.
    Woo J; Oh SJ; Song JY; Chae BJ; Choi JE; Lee J; Park HK; ; Lim W
    BMC Cancer; 2021 May; 21(1):647. PubMed ID: 34059020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.